Back

Seroprevalence of COVID-19 in HIV Population

Naik, S. R.; Kumar, S. S.; Mittal, A.; Swain, S.; Ranjan, S.; Soneja, M.; Sinha, S.; Nischal, N.; Jorwal, P.; Chaturvedi, P. K.; Wig, N.

2021-06-20 hiv aids
10.1101/2021.06.17.21259066 medRxiv
Show abstract

BackgroundSeroprevalence helps us to estimate the exact prevalence of a disease in a population. Although the world has been battling this pandemic for more than a year now, we still do not know about the burden of this disease in people living with HIV/AIDS (PLHA). Seroprevalence data in this population subset is scarce in most parts of the world, including India. The current study aimed to estimate the seroprevalence of anti-SARS-CoV-2 IgG antibody among PLHA. AimTo determine the seroprevalence of SARS-CoV-2 antibodies in PLHA. MethodThis was a cross-sectional study conducted at a tertiary care hospital in North India. We recruited HIV positive patients following at the ART centre of the institute. Anti-SARS-CoV-2 IgG antibody levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum sample by the chemiluminescent immunoassay method. ResultsA total of 164 patients were recruited in the study with a mean age ({+/-}SD) of 41.2 ({+/-}15.4) years, of which 55% were male. Positive serology against SARS CoV-2 was detected in 14% patients (95% CI: 9.1-20.3%). ConclusionThe seroprevalence of COVID-19 infection in PLHA was lower than the general population in the same region, which ranged from 23.48% to 28.3% around the study period.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.